EGFR and neoplasm: Furthermore, combined inhibition of VEGF (with bevacizumab) and the other RTK EGFR (with erlotinib) in a severe combined immunodeficient mouse xenotransplantation model led to a synergistic reduction in tumor volume, and this combination was effective also in decreasing the number of lymph node and lung metastases; this activity was associated with erlotinib-mediated impaired cell proliferation and synergistically increased apoptosis and reduced tumor angiogenesis (108).